The grant, plainly. On September 21, 2021, the Institute for Basic Science was issued US11123409B2, covering a method of treating eye disease using Cas9 protein and guide RNA. The CPC tags — A61K 38/465 (therapeutic nucleases), C12N 9/22, C12N 15/102 — describe a direct in-vivo editing approach delivered to the eye.
Why a catalyst desk maps it: the eye is a favored target for in-vivo editing because it is accessible and immune-privileged, and a cluster of companies are pursuing ocular editing programs. Foundational target IP like this defines the exclusivity space those programs operate in, and the clinical readouts from such programs are exactly the binary events a catalyst calendar tracks.
The disciplined read: an in-vivo editing method grant is an exclusivity claim on a technique, not a clinical outcome. The catalyst value sits in the data each program generates; the grant tells you the protected approach exists and what it covers.
What the grant does not say: nothing about which sponsor will read out when, nothing about efficacy or safety, and nothing about freedom to operate against competing editing estates. Those are separate facts in separate records.
The takeaway: when building a catalyst calendar around gene editing, use foundational target grants to understand the protected space behind each ocular program, then track the readouts separately. This September 2021 eye-disease Cas9 grant is a dated marker of that space.